INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 155 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2020. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,231,286 | -21.2% | 177,218 | -4.2% | 0.17% | -15.3% |
| Q2 2023 | $11,709,198 | +12.7% | 184,921 | -3.6% | 0.20% | -4.7% |
| Q1 2023 | $10,391,547 | +0.7% | 191,903 | -1.6% | 0.21% | -5.3% |
| Q4 2022 | $10,322,416 | +11.8% | 195,057 | -1.7% | 0.22% | +6.1% |
| Q3 2022 | $9,234,000 | -21.5% | 198,442 | -3.7% | 0.21% | -17.2% |
| Q2 2022 | $11,760,000 | -6.9% | 206,025 | -0.2% | 0.26% | +14.3% |
| Q1 2022 | $12,638,000 | +11.5% | 206,534 | -4.6% | 0.22% | +14.9% |
| Q4 2021 | $11,333,000 | +39.5% | 216,521 | -0.6% | 0.20% | +30.0% |
| Q3 2021 | $8,123,000 | -11.8% | 217,888 | -3.4% | 0.15% | -9.6% |
| Q2 2021 | $9,205,000 | +21.8% | 225,498 | +1.3% | 0.17% | +15.3% |
| Q1 2021 | $7,555,000 | -3.9% | 222,669 | -9.9% | 0.14% | -10.0% |
| Q4 2020 | $7,861,000 | +16.0% | 247,194 | -6.4% | 0.16% | -0.6% |
| Q3 2020 | $6,779,000 | -4.2% | 264,180 | -4.2% | 0.16% | -8.0% |
| Q2 2020 | $7,079,000 | – | 275,775 | – | 0.18% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
| Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
| DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
| Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
| Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
| Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |